MedTrace Logo

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

NCT05807542 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-05-16

No results posted yet for this study

Summary

Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Conditions

  • Esophagus Cancer

Interventions

DRUG

Tislelizumab

Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.

DRUG

Paclitaxel-albumin

Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.

DRUG

Carboplatin

carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-09-30
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05807542 on ClinicalTrials.gov